Against other GLP-1 receptor agonists, the relative risk was 1.08, essentially identical, with a confidence interval of 0.12 to 9.72
The pharmaceutical companies extensive marketing of these drugs (with Novo Nordisk and Eli Lilly commanding market dominance and generating billions in annual revenue) created widespread exposure among both diabetes patients and those seeking weight loss
With that said, theres not enough evidence to say that increasing oxygen is a viable option for 1) reducing androgen receptors, 2) reducing DHT levels, or 3) regrowing hair
While the overall market share of GLP-1 users is still emerging, the pace of adoption and the depth of behavioural change suggest this is a trend that warrants close attention
Consult a qualified healthcare provider to determine whether sermorelin therapy is appropriate for your situation
Our products, provided by Optimasupply, are specifically designed for LABORATORY RESEARCH ONLY